Comparison of the safety and pharmacokinetics of ST-246® after IV infusion or oral administration in mice, rabbits and monkeys

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Chen, Yali ^a   Amantana, Adams ^a   Tyavanagimatt, Shanthakumar R ^a   Zima, Daniela ^a   Yan, X Steven ^a   Kasi, Gopi ^a   Weeks, Morgan ^a   Stone, Melialani A ^a   Weimers, William C ^a   Samuel, Peter ^a   Tan, Ying ^a   Jones, Kevin F ^a   Lee, Daniel R ^a   Kickner, Shirley S ^a   Saville, Bradley M ^b   Lauzon, Martin ^b   McIntyre, Alan ^b   Honeychurch, Kady M ^a   Jordan, Robert ^a   Hruby, Dennis E ^a   Leeds, Janet M ^a   more..

^a SIGA Technologies Incorporated   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TECOVIRIMAT; ANTIVIRUS AGENT; BENZAMIDE DERIVATIVE; ISOINDOLE DERIVATIVE; ST-246;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HAPLORHINI; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RABBIT; TOXICOKINETICS; ANIMAL; BAGG ALBINO MOUSE; BIOAVAILABILITY; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG SCREENING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MACACA FASCICULARIS; METABOLIC CLEARANCE RATE; METHODOLOGY; ORAL DRUG ADMINISTRATION; TIME; TISSUE DISTRIBUTION; TREMOR;

MUS; ORTHOPOXVIRUS; ORYCTOLAGUS CUNICULUS; PRIMATES;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; AREA UNDER CURVE; BENZAMIDES; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; ISOINDOLES; MACACA FASCICULARIS; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; RABBITS; TIME FACTORS; TISSUE DISTRIBUTION; TREMOR;

EID: 80051681535     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023237     Document Type: Article

References (38)

1. Nafziger SD, (2005) Smallpox. Crit Care Clin 21 (4): 739-46.
2. Duclos P, Okwo-Bele J-M, Gacic-Dobo M, Cherian T, (2009) Global immunization: status, progress, challenges and future. BMC International Health and Human Rights 9 (Suppl 1): S2.
3. Bolken TC, Hruby DE, (2010) Tecovirimat for smallpox infections. Drugs Today (Barc) 46 (2): 109-17.
4. Parker S, Nuara A, Buller RM, Schultz DA, (2007) Human monkeypox: an emerging zoonotic disease." Future Microbiol 2: 17-34.
5. Kaiser J, (2007) A Tame Virus Runs Amok. Science 316 (5830): 1418-9.
6. Nitsche A, Kurth A, Pauli G, (2007) Viremia in human Cowpox virus infection. J Clin Virol 40 (2): 160-2.
7. Learned LA, Reynolds MG, Wassa DW, Li Y, Olson VA, et al. (2005) Extended interhuman transmission of monkeypox in a hospital community in the Republic of the Congo, 2003. Am J Trop Med Hyg 73 (2): 428-434.
8. Hutin YJ, Williams RJ, Malfait P, Pebody R, Loparev VN, et al. (2001) Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997. Emerg Infect Dis 7 (3): 434-8.
9. Eriksson U, Peterson LW, Kashemirov BA, Hilfinger JM, Drach JC, et al. (2008) Serine peptide phosphoester prodrugs of cyclic cidofovir: synthesis, transport, and antiviral activity. Mol Pharm 5 (4): 598-609.
10. Quenelle DC, Collins DJ, Kern ER, (2003) Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice." Antimicrob Agents Chemother 47 (10): 3275-80.
11. Smee DF, (2008) Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir Chem Chemother 19 (3) Review: 115-24.
12. Goff A, Twenhafel N, Garrison A, Mucker E, Lawler J, et al. (2007) In vivo imaging of cidofovir treatment of cowpox virus infection Virus Res 128 (1-2): 88-98.
13. Geerinck K, Lukito G, Snoeck R, De Vos R, De Clercq E, (2001) A case of human orf in an immunocompromised patient treated successfully with cidofovir cream. J Med Virol 64 (4): 543-9.
14. McCabe D, Weston B, Storch G, (2003) Treatment of orf poxvirus lesion with cidofovir cream Pediatr Infect Dis J 22 (11): 1027-8.
15. Baker RO, Bray M, Huggins JW, (2003) Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections." Antiviral Res 57 (1-2): 13-23.
16. Neyts J, De Clercq E, (2003) Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives Antiviral Res 57 (1-2): 25-33.
17. Lalezari JP, Holland GN, Kramer F, McKinley GF, Kemper CA, et al. (1998) Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS." J Acquir Immune Defic Syndr Hum Retrovirol 17 (4): 339-44.
18. Papastamopoulos V, Botsis C, Paparizos VA, Kyriakis KP, Zagoraios Y, et al. (2000) Stavrianeas NG. "Lack of reactivation of cytomegalovirus retinitis in an AIDS patient, during and after stopping long-term cidofovir treatment: case report." J Chemother 12 (3): 258-60.
19. Lalezari JP, Stagg RJ, Kuppermann BD, Holland GN, Kramer F, Ives DV, Youle M, Robinson MR, Drew WL, Jaffe HS, (1997) Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med 126 (4): 257-63.
20. Ciesla SL, Trahan J, Wan WB, Beadle JR, Aldern KA, et al. (2003) Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney." Antiviral Res Aug; 59 (3): 163-71.
21. Cono J, Casey CG, Bell DM, (2003) Smallpox Vaccination and Adverse Reactions." MMWR 52 (RR04): 1-28.
22. Rosenthal SR, Merchlinsky M, Kleppinger C, Goldenthal KL, (2001) Developing New Smallpox Vaccines." Emerging Infectious Diseases 7 (6): 920-6.
23. Massoudi MS, Barker L, Schwartz B, (2003) Effectiveness of postexposure vaccination for the prevention of smallpox: results of a delphi analysis." J Infect Dis 188 (7): 973-6.
24. Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, et al. (2005) An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol 79 (20): 13139-49.
25. Bailey TR, Rippin SR, Opsitnick E, Burns CJ, Pevear DC, et al. (2007) N-(3,3a,4,4a,5,5a,6,6a-Octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol-2-(1H)-yl)carboxamides: Identification of novel orthopoxvirus egress inhibitors. J Med Chem 50 (7): 1442-4.
26. Chen Y, Honeychurch KM, Yang G, Byrd CM, Harver C, et al. (2009) Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesis. Virol J 6 (44): 1-12.
27. Duraffour S, Snoeck R, deVos R, van Den Oord JJ, Crance J-M, et al. (2007) Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures. Antiviral Therapy 12: 1205-1216.
28. Quenelle DC, Buller RM, Parker S, Keith KA, Hruby DE, et al. (2007) Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice." Antimicrob Agents Chemother 51 (2): 689-95.
29. Sbrana E, Jordan R, Hruby DE, Mateo RI, Xiao SY, et al. (2007) Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection." Am J Trop Med Hyg 76 (4): 768-773.
30. Nalca A, Hatkin JM, Garza NL, Nichols DK, Norris SW, et al. (2008) Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model." Antiviral Res 79 (2): 121-7.
31. Huggins J, Goff A, Hensley L, Mucker E, Shamblin J, et al. (2009) Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob Agents Chemother 53 (6): 2620-5.
32. Jordan R, Goff A, Frimm A, Corrado ML, Hensley LE, et al. (2009) ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob Agents Chemother 53 (5): 1817-22.
33. Jordan R, Tien D, Bolken TC, Jones KF, Tyavanagimatt SR, et al. (2008) Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob Agents Chemother 52 (5): 1721-7.
34. Jordan R, Leeds JM, Tyavanagimatt S, Hruby DE, (2010) Development of ST-246® for Treatment of Poxvirus Infections. Viruses 2: 2409-2435.
35. Jordan R, Chinsangaram J, Bolken TC, Tyavanagimatt SR, Tien D, et al. (2010) Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. Antimicrob Agents Chemother 54 (6): 2560-6.
36. Vora S, Damon I, Fulginiti V, Weber SG, Kahana M, et al. (2008) Severe Eczema Vaccinatum in a Household Contact of a Smallpox Vaccinee. CID 46 (10): 1555-1561.
37. Centers for Disease Control and Prevention (CDC) (2009) Progressive Vaccinia in a Military Smallpox Vaccinee - United States, 2009. MMWR 58 (19): 532-536.
38. Guidance for Industry, Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug Administration, May 2001.